Остеопороз и остеопатии

Расширенный поиск


Список литературы

1. Беневоленская Л.И. Бисфосфонаты в терапии и профилактике остеопороза. // Росс. pевматол., 1998, 2, 2-9.

2. Беневоленская Л.И. Бисфосфонаты и остеопороз. // Рук. по остеопорозу (под ред. Проф. Л.И. Беневоленской). БИНОМ, М., 2003, 196-216.

3. Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение (ред. Л.И. Беневоленская, О.М. Лесняк). // М.: ГЭОТАР-Медиа. - 2005. - 171с.

4. Barrett J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. // J. Clin. Pharmacol. 2004; 44:951-965.

5. Bauss F., Kling L., Sponer G. Comparison of continuous and ciclical administration of ibandronate on bone mass in ovariectomized rats. //Bone Miner.Res., 1996, 11 (suppl. 1), S336

6. Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatol. 2002; 29:990-998.

7. Bauss F., Lalla S., Endele R. et al. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatol. 2002; 29:2200-2208.

8. Bauss F., Russel R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis Int. 2004; 15: 423-433.

9. Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. // Osteopor. Int., 2000, 11(supl.1), S26

10. Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. // J. Bone Miner. Res., 2004, 19, 1241-1249.

11. Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. // J.Clin. Endocrinol. Metab., 2003, 88, 4609-15.

12. Cranney A., Wells G., Willan A. et al. IX. Summary of metaanalyses of therapies for postmenopausal osteoporosis. // Endocr.Rev. 2002; 23:570-578.

13. Delmas P.D., R.R. Recker, Chesnut III C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. // Osteopor. Int., 2004, 15, 792-798.

14. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis Int. 1996; 6: 166-170.

15. Fleisch H. Bisphosphonates: mechanisms of action. // Endocr. Rev. 1998; 19:80-100.

16. Lalla S., Hothorn L.A., Hagg N. et al. Lifelong of high doses of ibandronate increases bone mass and maintains bone quality in lumbar vertebrae in rats. // Osteopor. Int., 1998, 8, 97-103.

17. Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. // J. Bone Miner. Res. 2005; 20: 1315-11322.

18. Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties. // J. Bone Miner. Res. 1999; 14: 1768-1778.

19. Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausl osteoporosis. // IJCP, 2003; 57: 417-422.

20. Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. // Bone, 1996, 19, 527-533.

21. Ravn P., Christiansen C., Baumann M.,Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. // Bone, 1998, 22, 559-564.

22. Recker R.R., Stakkestad J.A., Weber T. et al. Non-vertebral fracture benefit from oral ibandronate administrated daily or with a unique drug-free interval: results from a pivotal phase III study in postmenopausal osteoporosis (PMO). // J. Bone Miner. Res. 2002; 17 (suppl. 1): S134 (Abstract 1038).

23. Recker R., Weinstein R., Chesnut III C.H. et al. Long-term treatment with oral daily and intermittent ibandronate produces newly formed bone of normal quality in patients with postmenopausal osteoporosis. // Osteopor. Int. 2003; 14 (Suppl.7):S73 (Abstract P265).

24. Reginster J-Y., Wilson K.M., Dumount E. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. // J. Clin. Endocrinol.Metab. 2005; 90: 5018-5024.

25. Reginster J-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis. // Ann.Rheum. Dis. 2006; 65:654-661.

26. Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. // J. Bone Miner. Res., 2001,16, 1871-1878.

27. Smith S.Y., Recker R.R., Hannan M. et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // Bone 2003; 32:45-55.


Для цитирования:


For citation:


Просмотров: 257

ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)